Literature DB >> 34260846

Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. Reply.

Robert Motzer1, Toni K Choueiri2.   

Abstract

Entities:  

Year:  2021        PMID： 34260846     DOI： 10.1056/NEJMc2107518

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma.

Authors:  Yuki Nemoto; Hiroki Ishihara; Kazutaka Nakamura; Hidekazu Tachibana; Hironori Fukuda; Kazuhiko Yoshida; Hirohito Kobayashi; Junpei Iizuka; Hiroaki Shimmura; Yasunobu Hashimoto; Kazunari Tanabe; Tsunenori Kondo; Toshio Takagi
Journal:  Int Urol Nephrol       Date:  2021-10-26       Impact factor: 2.370

2.  Up-front Nivolumab With or Without Salvage Ipilimumab Across International Metastatic Database Consortium Risk Groups in Metastatic Clear Cell Renal Cell Carcinoma.

Authors:  Martin H Voss
Journal:  J Clin Oncol       Date:  2022-06-09       Impact factor: 50.717

3.  Supportive therapy and complementary medicine in renal cell carcinoma.

Authors:  M Johannsen; C Stoll; M Raida; B van Oorschot; A Flörcken
Journal:  World J Urol       Date:  2021-11-25       Impact factor: 3.661

4.  Expression of nectin-4 in papillary renal cell carcinoma.

Authors:  Franziska Erlmeier; Sandra Steffens; Stefanie Zschäbitz; Marie Mikuteit; Christine Stöhr; Edwin Herrmann; Iris Polifka; Abbas Agaimy; Lutz Trojan; Philipp Ströbel; Frank Becker; Christian Wülfing; Peter Barth; Michael Stöckle; Michael Staehler; Christian Stief; Axel Haferkamp; Markus Hohenfellner; Stefan Duensing; Stephan Macher-Göppinger; Bernd Wullich; Joachim Noldus; Walburgis Brenner; Frederik C Roos; Bernhard Walter; Wolfgang Otto; Maximilian Burger; Andres Jan Schrader; Arndt Hartmann
Journal:  Discov Oncol       Date:  2022-09-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.